Article in Science (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors.
Eve KandybaHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9219-5284
Arnaud JabouilleHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-2281-430X
Ferriol CalvetInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-1841-9881
Yun Rose LiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8077-4975
Andrea CurtabbiHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5185-4431
Diana CristeaHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0007-9225-1841
Joyce ShinHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0007-8443-1439
Reyno DelrosarioHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
Jonathan AnzulesDepartment of Radiation Oncology and Cancer Genetics and Epigenetics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.ORCID 0009-0004-2597-6728
Di WuHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0009-0001-7369-0220
David QuigleyHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-4726-1473
Mark TaylorHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2266-7917
Nuria Lopez-BigasInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0003-4925-8988
Allan BalmainHelen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6549-7861
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7M
PROMINENT - UCSFOT2CA278665 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2022 to 2026
$8.9M
Systems genetics analysis of tumor evolution in the mouseR35CA210018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2017 to 2026
$8.0M
Genetic network analysis of cancer targetsU01CA176287 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2013 to 2016
$1.2M
Genetic analysis of ras mutation specificity in skin and lung cancerR01CA184510 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN · 2015 to 2017
$1.1M
PROMINENT - IRBOT2CA278668 · NCI · FUNDACIO INSTITUT DE RECERCA BIOMEDICA · PI LOPEZ-BIGAS, NURIA · 2022 to 2024
$1.0M
Single cell analysis of the evolving mutational landscape in carcinogen exposed skinR50CA251479 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KANDYBA, EVE · 2020 to 2023
The identification of the cancer cell of origin is a fundamental issue in cancer biology. We used fluorescent lineage tracing of independent mouse skin stem cell populations, single-cell transcriptomics, and duplex sequencing to identify the origin of chemically induced skin tumors. Tumors arose predominantly from
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemically induced skin tumors arise from long-lived stem cells of the upper hair follicle. · full record | OpenQuestion